In nonobese patients in the ESSENCE trial, semaglutide improved metabolic dysfunction even with modest weight loss of 2% to 5%.
Jörn M. Schattenberg, MD
Advertisement
Articles by Jörn M. Schattenberg, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5